TY - JOUR
T1 - Adoptive immunotherapy for cancer
T2 - Harnessing the T cell response
AU - Restifo, Nicholas P.
AU - Dudley, Mark E.
AU - Rosenberg, Steven A.
N1 - Funding Information:
This work was supported by the Intramural Research Program of the Center for Cancer Research, US National Cancer Institute (NCI), National Institutes of Health. The authors would like to thank C. Klebanoff, L. Gattinoni, C. Hinrichs and P. Muranski for discussions about T cell differentiation, M. Bachinski for editorial help, E. Tran for critically reading the manuscript, and all the members of the translational immunology team at the NCI, especially J. C. Yang, P. F. Robbins, R. A. Morgan, R. M. Sherry, S. Feldman, M. Parkhurst, M. Hughes, G. Phan and U. Kammula.
PY - 2012/4
Y1 - 2012/4
N2 - Immunotherapy based on the adoptive transfer of naturally occurring or gene-engineered T cells can mediate tumour regression in patients with metastatic cancer. Here, we discuss progress in the use of adoptively transferred T cells, focusing on how they can mediate tumour cell eradication. Recent advances include more accurate targeting of antigens expressed by tumours and the associated vasculature, and the successful use of gene engineering to re-target T cells before their transfer into the patient. We also describe how new research has helped to identify the particular T cell subsets that can most effectively promote tumour eradication.
AB - Immunotherapy based on the adoptive transfer of naturally occurring or gene-engineered T cells can mediate tumour regression in patients with metastatic cancer. Here, we discuss progress in the use of adoptively transferred T cells, focusing on how they can mediate tumour cell eradication. Recent advances include more accurate targeting of antigens expressed by tumours and the associated vasculature, and the successful use of gene engineering to re-target T cells before their transfer into the patient. We also describe how new research has helped to identify the particular T cell subsets that can most effectively promote tumour eradication.
UR - http://www.scopus.com/inward/record.url?scp=84858758766&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858758766&partnerID=8YFLogxK
U2 - 10.1038/nri3191
DO - 10.1038/nri3191
M3 - Review article
C2 - 22437939
AN - SCOPUS:84858758766
SN - 1474-1733
VL - 12
SP - 269
EP - 281
JO - Nature Reviews Immunology
JF - Nature Reviews Immunology
IS - 4
ER -